NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026
This is a contract result notice, not an open opportunity. Details from the official award data.
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East.
Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months.
Lot 2 - Natalizumab for London and South of England.
The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
What this notice demands of you
1 named, none in explicit obligation language. Each one is quoted from the notice.
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East.
Matched against the notice text, so this is a floor — the tender pack will demand things the notice never mentions. “Says must” means the quoted sentence itself used obligation language; anything ambiguous is left as a mention.
Make the case to bid
Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- ocds-h6vhtk-051c98
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 068603-2026
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
NHS England’s tender network